Boor et al. observed that HHLA2 is expressed in 67% of PC and 93% of ampullary tumors, with high expression levels significantly associated with improved cancer-specific survival and delayed recurrence post-surgery, establishing HHLA2 as an independent prognostic marker (Boor et al. 2020). Here, HHLA2 is linked to pachyonychia congenita.